Month: June 2020

Pursuant to section 30 of the Danish Capital Market Act it is hereby announced that GAB Invest ApS in accordance with section 38,1 of the Danish Capital Market Act has informed Gabriel Holding A/S that GAB Invest ApS on 2 June 2020 has sold 50,000 shares in Gabriel Holding A/S corresponding to 2.65% of the share capital and voting rights in Gabriel Holding A/S.Following the sale of shares in Gabriel Holding A/S, GAB Invest ApS now holds 141,239 shares corresponding to 7.47% of the share capital and voting rights in Gabriel Holding A/S.AttachmentGabriel Holding AS – Announcement no 8 – Major holdings

Med henvisning til Kapitalmarkedslovens § 30 oplyses det hermed, at GAB Invest ApS i henhold til Kapitalmarkedslovens § 38, stk. 1, har meddelt Gabriel Holding A/S, at GAB Invest ApS d. 2. juni 2020 har solgt 50.000 stk. aktier i Gabriel Holding A/S svarende til 2,65% af aktiekapitalen og stemmerne i Gabriel Holding A/S.Efter salget af aktierne i Gabriel Holding A/S, har GAB Invest ApS en beholdning på i alt 141.239 aktier, svarende til 7,47% af aktiekapitalen og stemmerne i Gabriel Holding A/S.Vedhæftet filGabriel Holding AS – Meddelelse nr. 8 – Storaktionær

In accordance with Article 19 of the Market Abuse Regulation, Gabriel Holding A/S publishes the following transaction.AttachmentGabriel Holding AS – Announcement no 7 – Managers Transaction

I henhold til Markedsmisbrugsforordningen art. 19 offentliggør Gabriel Holding A/S følgende transaktion.Vedhæftet filGabriel Holding AS – Meddelelse nr. 7 – transaktion ledende medarbejder

MONMOUTH JUNCTION, N.J., June 03, 2020 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the Company), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced the successful closing of its previously announced private placement of $16.0 million of common stock at a price of $1.00 per share (representing a 34% premium at signing) to Syntone Ventures LLC, a U.S.-based affiliate of Syntone Technologies Group Co. Ltd.Outlook Therapeutics intends to use the net proceeds from the financing for working capital and general corporate purposes, including in support of its development program for ONS-5010 / LYTENAVA™ (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab to treat wet AMD,...

CHESTERBROOK, Pa., June 03, 2020 (GLOBE NEWSWIRE) — Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the Company’s partner in China has been approved by the Chinese National Medical Products Administration (NMPA) to initiate clinical trials for IV oliceridine, Trevena’s lead investigational asset for the management of moderate-to-severe acute pain. Jiangsu Nhwa holds an exclusive license agreement for the development and commercialization of oliceridine in China.“I am pleased to have reached this important regulatory milestone for IV oliceridine ,” said Carrie Bourdow, President and Chief Executive Officer of Trevena, Inc. “As we work towards our August 7th PDUFA date for potential...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVANCOUVER, British Columbia, June 03, 2020 (GLOBE NEWSWIRE) — Luminex Resources Corp. (TSXV: LR) (the “Company” or “Luminex”) is pleased to announce that it has entered into an agreement with a syndicate of agents, led by Haywood Securities Inc. (collectively, the “Agents”), that have agreed to sell, on a commercially reasonable efforts private placement basis, up to 9,286,000 common shares (“Shares”) at a price of C$0.70 per Share (the “Offering Price”), for aggregate gross proceeds of up to C$6,500,200 (the “Brokered Offering”). In addition, the Company intends to complete a concurrent non-brokered private placement of up to C$3,500,000 worth of Shares (the “Non-Brokered Offering”, and together with the Brokered Offering, the “Offering”),...

NEW YORK, June 03, 2020 (GLOBE NEWSWIRE) — Warner Music Group, its directors and management, and the Blavatnik Family Foundation announced today a $100 million fund to support charitable causes related to the music industry, social justice and campaigns against violence and racism.An advisory panel made up of appointees from Warner Music Group and the Blavatnik Family Foundation will establish procedures to identify and support those in the music community, and organizations strengthening education, and promoting equality, opportunity, diversity and inclusion. The advisory panel will determine the amount of the financial gifts and timing.Steve Cooper, CEO, Warner Music Group said, “This fund will support the extraordinary, dedicated organizations that are on the front lines of the fight against racism and injustice, and that help...

VANCOUVER, British Columbia, June 03, 2020 (GLOBE NEWSWIRE) — Norseman Capital Ltd. (NEX: NOC.H) (“Norseman” or the “Company”) is pleased to an announce that it has entered into an option agreement (the “Option Agreement”) with Cloudbreak Discovery Corp. (“Cloudbreak”) to acquire a 100% interest in certain mining claims located in the Skeena Mining Division area in British Columbia (the “Caribou Property”). The entering into of the Option Agreement is subject to the approval of the TSX Venture Exchange (the “Exchange”).Pursuant to the Option Agreement, in order to fully exercise the option (the “Option”), the Company shall pay to Cloudbreak an aggregate of $80,000 and 2,750,000 common shares in the capital of the Company (“Common Shares”) in three installments.The first installment is composed of $10,000, payable on the effective...

EMERYVILLE, Calif., June 03, 2020 (GLOBE NEWSWIRE) — NMI Holdings, Inc. (Nasdaq: NMIH) (the “Company”) today announced that it commenced an offering through a private placement of $300,000,000 aggregate principal amount of senior secured notes due 2025 (the “Notes”). Net proceeds from the Notes offering are intended to be used to repay the Company’s existing $147 million term loan and for general corporate purposes, including potential capital contributions to support the growth of new business production and operations of our subsidiaries.The Notes are being offered in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”) and to non-U.S. persons in accordance with Regulation S under the Securities Act.  The Notes have not been registered under...